8
Oct
2024

Mabion SA

Exhibitor at CPHI Milan 2024 stand 5B98, Contract Manufacturing and Services
About Us

Mabion is a fully integrated CDMO offering a wide array of services associated with the development and manufacturing of protein-based biotherapeutics, including monoclonal antibodies and vaccine antigens. With 16 years' experience, Mabion offers an “end-to-end” solution, covering all stages of biologic drug development, from early clone selection and small-scale manufacturing through process scale-up, large-scale manufacturing and quality control down to sterile fill-finish, packaging and serialization, bioanalytics and regulatory support.

  • PL
  • 2023
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Clinical Research
Contract Manufacturer
Contract Research Organisation
End-product distributor (Wholesale)
Intermediates Manufacturer
Contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 5B98, Contract Manufacturing and Services

Products Featured at CPHI Milan 2024

  • MabionCD20

    Product MabionCD20

    This is our most advanced in-house project. A MabThera/Rituxan (rituximab) biosimilar drug, whose efficacy and safety were clinically confirmed. It is the first such advanced drug developed in Poland. We are currently at the final stage of works aimed at marketing the drug in Europe and the United States.